TrialBlood advances2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML.
Nigel Russell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it